Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone
The review found no eligible studies for this question.
- no estimate extractedStudies not reportedNo studies found
Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Oral methotrexate plus intra‐articular glucocorticoid showed no clear difference in withdrawals due to adverse events(12 months) compared with intra‐articular glucocorticoid alone (low certainty).
The review found no eligible studies for this question.
Methotrexate showed no clear difference in treatment responsea(4 months) compared with alternative disease‐modifying antirheumatic drugs (low certainty).
The review found no eligible studies for this question.
Methotrexate may leads to higher treatment responsea(up to 6 months) compared with placebo (low certainty).
The review found no eligible studies for this question.
Methotrexate showed no clear difference in serious adverse events(4 months) compared with alternative disease‐modifying antirheumatic drugs (low certainty).
Methotrexate showed no clear difference in withdrawals due to adverse events(4 months) compared with alternative disease‐modifying antirheumatic drugs (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Methotrexate showed no clear difference in participant global assessment of well‐being(up to 6 months) compared with placebo (low certainty).
Methotrexate showed no clear difference in serious adverse events(up to 6 months) compared with placebo (low certainty).
Methotrexate showed no clear difference in withdrawals due to adverse events (up to 6 months) compared with placebo (low certainty).